Results 11 to 20 of about 43,468 (306)
Mode and site of action of therapies targeting CGRP signaling
The Journal of Headache and Pain, 2023 Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system.
Alejandro Labastida-Ramírez +12 more
semanticscholar +1 more source
Клинический разбор в общей медицине, 2023 Background. Menstrual related migraine (MRM) occurs in 60% of women with migraine. These attacks are characterized by high intensity and poor response to abortive and prophylactic treatment.
Anna V. Berdnikova +4 more
doaj +1 more source
Journal of Neurology, 2016 Migraine has been estimated to be the seventh highest cause of disability worldwide, and the third most common disease worldwide after dental caries and tension type headache. However, the use of currently available acute and prophylactic medications to control this condition, such as 5-HT1 agonists (triptans) and beta-blockers, is limited by side ...
Cauchi, M., Robertson, Neil
openaire +2 more sources
The Journal of Headache and Pain, 2009 Dear Editor,Concentrations of substances in plasma, in this case CGRP,can be presented in several different to ways, such as pmol/l[1–7], pg/ml [8, 9] and just recently as ng/ml [10]. Thesedifferent concentrations can be compared when one usesthe molecular weight of 3,790 for CGRP but it takes 5–10 min of arithmetic to do that.
Tfelt-Hansen, Peer, Ashina, Messoud
openaire +3 more sources
Cephalalgia, 2021 Background Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody (mAb), but there are no efficacy data so far.
L. H. Overeem +8 more
semanticscholar +1 more source
Migraine therapeutics differentially modulate the CGRP pathway
Cephalalgia, 2021 Background The clinical efficacy of migraine therapeutic agents directed towards the calcitonin-gene related peptide (CGRP) pathway has confirmed the key role of this axis in migraine pathogenesis.
Minoti Bhakta +5 more
semanticscholar +1 more source
Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
Saudi Journal of Medicine and Medical Sciences, 2023 Migraine is a potentially disabling disorder, yet it remains underdiagnosed and undertreated. The release of the neuropeptide calcitonin gene-related peptide (CGRP) in the trigemino-cerebrovascular system plays a vital role in the evolution of migraine ...
Suruchi Aditya, Aditya Rattan
doaj +1 more source
CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
Frontiers in Neurology, 2022 The multi-functional neuropeptide calcitonin gene-related peptide (CGRP) plays a major role in the pathophysiology of migraine. The detection of elevated CGRP levels during acute migraine headache was the first evidence of the importance of the peptide ...
K. Kamm
semanticscholar +1 more source
New Anti-CGRP Medications in the Treatment of Vestibular Migraine
Frontiers in Neurology, 2022 Background Vestibular migraine (VM) is a condition associated with migraine headache, vertigo, dizziness, and balance disturbances. Treatment options are limited.
Justin L Hoskin, T. Fife
semanticscholar +1 more source
Anti-CGRP antibodies block CGRP-induced diarrhea in mice [PDF]
Neuropeptides, 2017 The multifunctional neuropeptide calcitonin gene-related peptide (CGRP) and its receptor are expressed throughout the gastrointestinal tract. Previous studies have shown that CGRP has roles in intestinal motility, water secretion, and inflammation. Furthermore, animal studies have demonstrated CGRP involvement in diarrhea secondary to C.
Eric A, Kaiser +6 more
openaire +2 more sources